Dr. Davids on the Phase II CRC043 Trial for Patients With Richter's Transformation
Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter
Matthew S. Davids, MD, MMSc, associate director, Center for Lymphocytic Leukemia, physician, Dana-Farber Cancer Institute, and assistant professor of medicine, Harvard Medical School, discusses the use of the BCL‐2 inhibitor, venetoclax (Venclexta) with dose-adjusted infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (R-EPOCH) to treat patients with Richter’s transformation.
In CLL, there have been a number of systemic therapies approved to move the paradigm forward. However, Richter's transformation is still an unmet need that physicians contend with, and the condition does not normally respond to the available single agents, leading to the combination strategy.
In the phase II study, investigators evaluated the addition of R-EPOCH with venetoclax, which can be utilized as a chemotherapy-sensitizing agent.
